Two ‘Step-Changing’ Drugs For Waldenström’s Macroglobulinemia Fail To Win English Funding
Executive Summary
NICE has issued final guidance for Imbruvica and preliminary guidance for Brukinsa, saying that while clinical evidence supports using the BTK inhibitors for WM, it is not convinced that either drug will be a cost-effective use of National Health Service resources.